Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2021)
Xeris Biopharma Holdings (XERS) posted Gains from Investment Securities of $793000.0 for Q4 2021, up 1079.01% on a QoQ basis from -$81000.0 in Q3 2021, and up 1541.82% year-over-year from $48300.1 in Q4 2020.
Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2021) Analysis & Trends
Xeris Biopharma Holdings' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $793000.0 for Q4 2021.
- Quarterly Gains from Investment Securities rose 1541.82% year-over-year to $793000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $817000.0 (changed N/A YoY) and the FY2021 annual result came in at $702000.0, up 7700.0% from the prior year.
- Gains from Investment Securities was $793000.0 for Q4 2021 at Xeris Biopharma Holdings, up from -$81000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $793000.0 in Q4 2021 and bottomed at -$81000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.41 Bn | 1.30 Bn | 72.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 793,000.00 |
| Dec 31, 2021 | 793,000.00 |
| Sep 30, 2021 | -81,000.00 |
| Sep 30, 2021 | -81,000.00 |
| Dec 31, 2020 | -55,000.00 |
| Dec 31, 2020 | -55,000.00 |
| Sep 30, 2020 | 160,000.00 |
| Sep 30, 2020 | 160,000.00 |